What we are learning on HTLV-1 pathogenesis from animal models

Madeleine Duc Dodon, Julien Villaudy, Louis Gazzolo, Robyn Haines, Michael Dale Lairmore

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Isolated and identified more than 30 years ago, human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma, an aggressive lymphoprolif-erative disease of activated CD4+ T cells, and other inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis. A variety of animal models have contributed to the fundamental knowledge of HTLV-1 transmission, pathogenesis, and to the design of novel therapies to treat HTLV-1-associated diseases. Small animal models (rabbits, rats, and mice) as well as large animal models (monkeys) have been utilized to significantly advance characterization of the viral proteins and of virus-infected cells in the early steps of infection, as well as in the development of leukemogenic and immunopathogenic processes. Over the past two decades, the creation of new immunocompromised mouse strains that are robustly reconstituted with a functional human immune system (HIS) after being transplanted with human tissues or progenitor cells has revolutionized the in vivo investigation of viral infection and pathogenesis. Recent observations obtained in HTLV-1-infected humanized HIS mice that develop lymphomas provide the opportunity to study the evolution of the proviral clonality in human T cells present in different lymphoid organs. Current progress in the improvement of those humanized models will favor the testing of drugs and the development of targeted therapies against HTLV-1-associated diseases.

Original languageEnglish (US)
Article numberArticle 320
JournalFrontiers in Microbiology
Volume3
Issue numberAUG
DOIs
StatePublished - 2012

Fingerprint

Deltaretrovirus
Animal Models
Learning
Immune System
Tropical Spastic Paraparesis
T-Lymphocytes
Adult T Cell Leukemia Lymphoma
Spinal Cord Diseases
Viral Proteins
Virus Diseases
Haplorhini
Lymphoma
Stem Cells
Rabbits
Viruses
Therapeutics
Infection
Pharmaceutical Preparations

Keywords

  • Animal model
  • HTLV
  • Human immune system
  • Immunocompromised mouse
  • Leukemia
  • Retrovirus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

What we are learning on HTLV-1 pathogenesis from animal models. / Duc Dodon, Madeleine; Villaudy, Julien; Gazzolo, Louis; Haines, Robyn; Lairmore, Michael Dale.

In: Frontiers in Microbiology, Vol. 3, No. AUG, Article 320, 2012.

Research output: Contribution to journalArticle

Duc Dodon, Madeleine ; Villaudy, Julien ; Gazzolo, Louis ; Haines, Robyn ; Lairmore, Michael Dale. / What we are learning on HTLV-1 pathogenesis from animal models. In: Frontiers in Microbiology. 2012 ; Vol. 3, No. AUG.
@article{1627137c9ac64eb0b0aa49e9d5d9a7e2,
title = "What we are learning on HTLV-1 pathogenesis from animal models",
abstract = "Isolated and identified more than 30 years ago, human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma, an aggressive lymphoprolif-erative disease of activated CD4+ T cells, and other inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis. A variety of animal models have contributed to the fundamental knowledge of HTLV-1 transmission, pathogenesis, and to the design of novel therapies to treat HTLV-1-associated diseases. Small animal models (rabbits, rats, and mice) as well as large animal models (monkeys) have been utilized to significantly advance characterization of the viral proteins and of virus-infected cells in the early steps of infection, as well as in the development of leukemogenic and immunopathogenic processes. Over the past two decades, the creation of new immunocompromised mouse strains that are robustly reconstituted with a functional human immune system (HIS) after being transplanted with human tissues or progenitor cells has revolutionized the in vivo investigation of viral infection and pathogenesis. Recent observations obtained in HTLV-1-infected humanized HIS mice that develop lymphomas provide the opportunity to study the evolution of the proviral clonality in human T cells present in different lymphoid organs. Current progress in the improvement of those humanized models will favor the testing of drugs and the development of targeted therapies against HTLV-1-associated diseases.",
keywords = "Animal model, HTLV, Human immune system, Immunocompromised mouse, Leukemia, Retrovirus",
author = "{Duc Dodon}, Madeleine and Julien Villaudy and Louis Gazzolo and Robyn Haines and Lairmore, {Michael Dale}",
year = "2012",
doi = "10.3389/fmicb.2012.00320",
language = "English (US)",
volume = "3",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - What we are learning on HTLV-1 pathogenesis from animal models

AU - Duc Dodon, Madeleine

AU - Villaudy, Julien

AU - Gazzolo, Louis

AU - Haines, Robyn

AU - Lairmore, Michael Dale

PY - 2012

Y1 - 2012

N2 - Isolated and identified more than 30 years ago, human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma, an aggressive lymphoprolif-erative disease of activated CD4+ T cells, and other inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis. A variety of animal models have contributed to the fundamental knowledge of HTLV-1 transmission, pathogenesis, and to the design of novel therapies to treat HTLV-1-associated diseases. Small animal models (rabbits, rats, and mice) as well as large animal models (monkeys) have been utilized to significantly advance characterization of the viral proteins and of virus-infected cells in the early steps of infection, as well as in the development of leukemogenic and immunopathogenic processes. Over the past two decades, the creation of new immunocompromised mouse strains that are robustly reconstituted with a functional human immune system (HIS) after being transplanted with human tissues or progenitor cells has revolutionized the in vivo investigation of viral infection and pathogenesis. Recent observations obtained in HTLV-1-infected humanized HIS mice that develop lymphomas provide the opportunity to study the evolution of the proviral clonality in human T cells present in different lymphoid organs. Current progress in the improvement of those humanized models will favor the testing of drugs and the development of targeted therapies against HTLV-1-associated diseases.

AB - Isolated and identified more than 30 years ago, human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma, an aggressive lymphoprolif-erative disease of activated CD4+ T cells, and other inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis. A variety of animal models have contributed to the fundamental knowledge of HTLV-1 transmission, pathogenesis, and to the design of novel therapies to treat HTLV-1-associated diseases. Small animal models (rabbits, rats, and mice) as well as large animal models (monkeys) have been utilized to significantly advance characterization of the viral proteins and of virus-infected cells in the early steps of infection, as well as in the development of leukemogenic and immunopathogenic processes. Over the past two decades, the creation of new immunocompromised mouse strains that are robustly reconstituted with a functional human immune system (HIS) after being transplanted with human tissues or progenitor cells has revolutionized the in vivo investigation of viral infection and pathogenesis. Recent observations obtained in HTLV-1-infected humanized HIS mice that develop lymphomas provide the opportunity to study the evolution of the proviral clonality in human T cells present in different lymphoid organs. Current progress in the improvement of those humanized models will favor the testing of drugs and the development of targeted therapies against HTLV-1-associated diseases.

KW - Animal model

KW - HTLV

KW - Human immune system

KW - Immunocompromised mouse

KW - Leukemia

KW - Retrovirus

UR - http://www.scopus.com/inward/record.url?scp=84875781038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875781038&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2012.00320

DO - 10.3389/fmicb.2012.00320

M3 - Article

C2 - 22969759

AN - SCOPUS:84875781038

VL - 3

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - AUG

M1 - Article 320

ER -